Jefferies Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)
Jefferies analyst Dennis Ding maintained a Buy rating on Rhythm Pharmaceuticals with a $125 price target. Ding, a 4-star analyst, has a 9.3% average return and a 50% success rate. Canaccord Genuity also issued a Buy rating, while TR | OpenAI reiterated a Hold rating. Ding focuses on the Healthcare sector, covering stocks like Mineralys Therapeutics and Amicus.
Jefferies analyst Dennis Ding maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $125.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Ding is a 4-star analyst with an average return of 9.3% and a 50.00% success rate. Ding covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Amicus, and Rhythm Pharmaceuticals.
In addition to Jefferies, Rhythm Pharmaceuticals also received a Buy from Canaccord Genuity’s Whitney Ijem in a report issued on November 10. However, on November 5, TR | OpenAI – 4o reiterated a Hold rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).
